Literature DB >> 29312802

EGFRwt/vIII-PKM2-β-catenin cascade affects proliferation and chemo-sensitivity in head and neck squamous cell carcinoma.

Chao Jing1,2,3, Xin Qu4, Zhaoqing Li1,2,3, Chuanqiang Wu1,2,3, Minghui Zhao1,2,3, Yu Wang1,2,3, Shanshan Sun1,2,3, Shengchi Zhang1,2,3, Jinliang Chen1,2,3, Yu Qiao1,2,3, Xiaomeng Hu1,2,3, Xiaofeng Yao1,2,3, Rui Jin1,2,3, Xudong Wang1,2,3, Lun Zhang1,2,3, Xuan Zhou1,2,3.   

Abstract

Patients suffered from head and neck squamous cell carcinoma (HNSCC) have an overall poor prognosis owing to proliferation and resistance to treatment. Hence, mining the underlying mechanism of malignancies above and translating the bench outcomes to clinical practice are in urgent need. Previous studies found that the epidermal growth factor receptor (EGFR) increases and co-expresses with EGFRvIII in HNSCC tissues, which indicates poor prognosis of HNSCC patients. Here, we clarify that compared with EGFRwt, EGFRwt/vIII enhances the capability of proliferation and colony formation in HNSCC cells in vitro, and reduces the sensitivity to cisplatin. Furthermore, EGFRwt/vIII induces nuclear translocation of the M2 isoform of pyruvate kinase (PKM2) in a time-dependent manner. The aberrant expression of PKM2 in HNSCC suggests unfavorable outcome. Especially, nuclear PKM2 determines the activation of β-catenin signaling and regulates the proliferation and chemo-sensitivity of HNSCC cells. Together, our findings demonstrate that EGFRwt/vIII-PKM2-β-catenin cascade controls the proliferation and chemo-sensitivity of HNSCC, thereby providing a promising strategy for diagnosis and therapy of HNSCC.

Entities:  

Keywords:  EGFRvIII; HNSCC; PKM2; chemo-sensitivity; proliferation; β-catenin

Year:  2017        PMID: 29312802      PMCID: PMC5752689     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  37 in total

Review 1.  Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Authors:  Mayumi Tamada; Makoto Suematsu; Hideyuki Saya
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

Review 2.  Regulation and function of pyruvate kinase M2 in cancer.

Authors:  Weiwei Yang; Zhimin Lu
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

3.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

4.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

Authors:  B Altenberg; K O Greulich
Journal:  Genomics       Date:  2004-12       Impact factor: 5.736

Review 5.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

6.  A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.

Authors:  Shlomo Handeli; Julian A Simon
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

7.  Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.

Authors:  Keith Syson Chan; Steve Carbajal; Kaoru Kiguchi; John Clifford; Shigetoshi Sano; John DiGiovanni
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

8.  Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.

Authors:  Lei Ma; Gong Zhang; Xiao-Bo Miao; Xu-Bin Deng; Yue Wu; Ying Liu; Zhi-Ru Jin; Xi-Qing Li; Qiu-Zhen Liu; Du-Xin Sun; Joseph R Testa; Kai-Tai Yao; Guang-Hui Xiao
Journal:  FEBS J       Date:  2013-04-08       Impact factor: 5.542

9.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

10.  WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.

Authors:  Xuan Zhou; Yu Ren; Aiqin Liu; Rui Jin; Qingping Jiang; Yuanyuan Huang; Lingping Kong; Xudong Wang; Lun Zhang
Journal:  Sci Rep       Date:  2014-12-17       Impact factor: 4.379

View more
  2 in total

1.  PKM2 regulates proliferation and apoptosis through the Hippo pathway in oral tongue squamous cell carcinoma.

Authors:  Jia Luo; Lei Zhang; Lijuan Guo; Sen Yang
Journal:  Oncol Lett       Date:  2021-04-11       Impact factor: 2.967

2.  Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC.

Authors:  Hanyue Chang; Qiaoshi Xu; Jiayi Li; Mingyu Li; Zhiyuan Zhang; Hailong Ma; Xi Yang
Journal:  Cell Death Dis       Date:  2021-07-21       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.